Skip to main content
. 2021 Mar 4;11(10):4790–4808. doi: 10.7150/thno.57456

Figure 5.

Figure 5

Cardiomyocyte number expansion drives LV growth and increases in LV contractile function after DUSP5 siRNA+T3 therapy. (A) Experimental protocol for testing the effects of the cell cycle inhibitor, danusertib, on T3-stimulated increases in LV dimensions and contractile function in DUSP5 siRNA-treated mice. (B) T3-stimulated increase in ventricular cardiomyocyte numbers in DUSP5 siRNA+T3 treated mice are blocked by danusertib (n = 6-8 mice per group); **P < 0.01. (C-G) In vivo echocardiographic evaluation of T3-stimulated changes in LV mass (C), LV PW dimensions, at diastole, at the LV mid-papillary level (D) and at the LV apex (E), LV ejection fraction (F) and LV fractional shortening (G) in DUSP5 siRNA+T3 treated mice, with or without danusertib treatment (n = 10 mice per group); **P < 0.01, ****P < 0.0001. Individual data points and mean ± s.e.m are shown. Comparisons were made using ANOVA with Sidak multiple comparison test; only within group P-values are shown (B-G).